Prot# AEG35156-206: An Open-Label Randomized Phase 2 Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given in Combination with High-Dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based

  • Tallman, Martin Stuart (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date11/11/09 → 11/11/12

Funding

  • Aegera Therapeutics Inc. (AEG35156-206)